AstraZeneca Pharma India (506820) Q2 25/26 earnings summary

Executive summary

• Achieved 37% year-over-year revenue growth in Q2 FY2025-26, driven by strong performance across Oncology, Biopharmaceuticals, and Rare Disease therapy areas.

• Seven new regulatory approvals in H1 reinforced leadership in key therapy areas and expanded the product portfolio.

• Ceased operations at the Bangalore manufacturing site and classified related assets as held for sale, aligning with strategic restructuring.

Financial highlights

• Q2 FY2025-26 revenue from operations was ₹5,590.9 million, up from ₹4,080.0 million in Q2 FY2024-25.

• Profit before exceptional items and tax for Q2 was ₹781.1 million, compared to ₹510.3 million in the prior year quarter.

• Profit after tax for Q2 was ₹542.2 million, up from ₹384.3 million year-over-year.

• Earnings per share for Q2 stood at ₹21.69, compared to ₹15.37 in Q2 last year.

• Cash and cash equivalents at September 30, 2025, were ₹3,993.9 million, down from ₹5,361.4 million at March 31, 2025.

Outlook and guidance

• Management emphasized continued focus on innovation, partnerships, and patient-centricity to drive sustainable, long-term growth.

• Strategic restructuring and portfolio expansion are expected to support future growth and leadership in therapy areas.